In December 2025, FDA warned that counterfeit Ozempic injection 1 mg had been found in the legitimate U.S. drug supply chain. FDA said it was notified by Novo Nordisk in November 2025, that the agency’s investigation was ongoing, and that retail pharmacies, wholesalers, health care professionals, and patients should closely inspect products for signs of counterfeit labeling. FDA also warned that counterfeit needles associated with the product raised sterility concerns, creating the possibility of infection.
That is an important pharmacy-error story because it shifts attention to a form of medication danger that patients do not always think about. Many people hear “pharmacy mistake” and think of the wrong bottle or the wrong instructions. Those cases matter, but medication safety failures can also involve sourcing, verification, packaging review, and the breakdown of safeguards that are supposed to stop suspect products before they reach a patient.
This issue is especially significant because Ozempic is a widely recognized medication, and a patient receiving a counterfeit version may have no obvious reason to doubt what they were handed. FDA’s broader guidance on counterfeit medicine explains that counterfeit drugs may contain the wrong ingredients, too much or too little active ingredient, no active ingredient at all, or other harmful ingredients.
Pharmacy Error Injury Lawyer Blog


